International Federation ORL Societies (IFOS) Executive Board members, Rome, Italy.
AOU Città della Salute e della Scienza di Torino, Regina Margherita Children's Hospital, Turin, Italy.
BMC Prim Care. 2022 Nov 23;23(1):296. doi: 10.1186/s12875-022-01901-w.
Benzydamine hydrochloride is a locally-acting Non-Steroidal Anti-Inflammatory Drug (NSAID) with combined local anesthetic and analgesic properties, indicated for the symptomatic relief of pain in acute sore throat. The aim of this study was to obtain an European Consensus among pharmacists, general practitioners and pediatricians on the appropriate use of benzydamine hydrochloride in the treatment of sore throat.
The authors developed a Delphi questionnaire organized into 15 statements focused on 4 topics: the mechanism of action of benzydamine, the benzydamine treatment in an adult patient and in a pediatric patient, and the advantages of benzydamine over other topical treatments. The survey was administered to a panel of to 320 participants including general practitioners, pediatricians, and pharmacists from 6 European countries (Italy, Germany, Portugal, Romania, Russia, and Spain), who rated their level of agreement or disagreement with each statement on a 6-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with each statement.
Panelists' agreement on statements was very high. Consensus was reached for all 15 statements in the Delphi survey, with more than 98% positive agreement on topic 4, suggesting a shared view among European healthcare professionals (HCPs) about the advantages of benzydamine over other topical treatments. A strong consensus (> 99%) was reached for all the statements of topic 1 regarding the mechanism of action of benzydamine, except for its anesthetic properties (79%). Strong agreement was reached for all statements in topics 2 and 3 regarding the treatment of acute sore throat symptoms in the adult and pediatric patient, except for one on the efficacy of benzydamine in preventing post-operative sore throat, for which it was 67%.
Because all relevant publications on benzydamine are dated and there are no recommendations on its use for the symptomatic treatment of sore throat in European guidelines, this Delphi-based international consensus may be important in reinforcing the appropriate use and effect of benzydamine in the treatment of sore throat among health care professionals.
盐酸苯佐卡因是一种局部作用的非甾体抗炎药（NSAID），具有局部麻醉和镇痛作用，用于缓解急性咽痛的疼痛症状。本研究旨在通过药师、全科医生和儿科医生之间的欧洲共识，获得盐酸苯佐卡因治疗咽痛的合理使用方法。
作者开发了一份德尔菲问卷，共 15 个条目，重点关注 4 个主题：苯佐卡因的作用机制、苯佐卡因在成年患者和儿科患者中的治疗作用，以及苯佐卡因与其他局部治疗方法的优势。该调查对来自 6 个欧洲国家（意大利、德国、葡萄牙、罗马尼亚、俄罗斯和西班牙）的 320 名普通科医生、儿科医生和药剂师进行了调查，他们对每个问题的同意或不同意程度进行了 6 点李克特量表评分。共识定义为超过 66%的专家组对每个问题的同意/不同意。
专家组对各项声明的意见非常一致。在德尔菲调查的 15 项声明中均达成共识，其中 4 主题的正面同意率超过 98%，表明欧洲医疗保健专业人员（HCP）对苯佐卡因优于其他局部治疗方法的优势有共同的看法。除了其麻醉作用（79%）外，在关于苯佐卡因作用机制的所有主题 1 声明中都达成了强烈共识（>99%）。在关于成人和儿科患者急性咽痛症状治疗的所有主题 2 和 3 声明中都达成了强烈同意，除了一项关于苯佐卡因预防术后咽痛的疗效的声明，同意率为 67%。
由于所有关于苯佐卡因的相关出版物都是陈旧的，欧洲指南中没有关于其用于治疗咽痛症状的建议，因此基于德尔菲的国际共识可能对加强医疗保健专业人员在治疗咽痛时对苯佐卡因的合理使用和效果很重要。
